Skip to content

Efficacy evaluation of auricular acupuncture combined with intravenous infusion therapy in the treatment of pregnancy nausea and vomiting: A protocol of randomized controlled trial

Efficacy evaluation of auricular acupuncture combined with intravenous infusion therapy in the treatment of pregnancy nausea and vomiting: A protocol of randomized controlled trial

Status
Unknown
Phases
Phase 1
Study type
Interventional
Source
TCTR
Registry ID
TCTR20220331005
Enrollment
45
Registered
2022-03-31
Start date
2022-04-29
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pregnancy nausea and vomiting are common symptoms during pregnancy, which seriously affects the quality of life of pregnant women. Intravenous infusion therapy is a common treatment at present, but the clinical efficacy is inefficacious when used alone. There is evidence that auricular acupuncture has advantages in treating nausea and vomiting in pregnancy, but there is currently a lack of rigorous randomized controlled studies to verify the efficacy of auricular acupuncture combined with intrav

Interventions

we will alternately select Shenmen(TF4), Wei(CO4), Jiaogan(AH6a), Neifenmi(CO18), Pizhixia(AT4) of the left and right ears as the operation sites, use 75% alcohol to disinfect the operation site, and
Experimental Other

Sponsors

Ya Zou
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 40 Years

Inclusion criteria

Inclusion criteria: 1.Patients consistent with the diagnosis of pregnancy nausea and vomiting 2.Age: 18 to 40 years old 3.Patients who has positive urine pregnancy test 4.Patients with intrauterine pregnancy showed by B ultrasound; Patients with 7 to 14 weeks of gestation 5.Patients whose liver function and kidney function are normal.

Exclusion criteria

Exclusion criteria: 1.Patients who had a history of severe nausea and vomiting before pregnancy 2.Patients with gastroenteritis, biliary tract infection, hepatitis, appendicitis and other diseases 3.Patients with serious systemic diseases, such as diabetes, cardiovascular diseases, etc. 4.Patients allergy to test drug or tool.

Design outcomes

Primary

MeasureTime frame
Pregnancy-Unique Quantification of Emesis and Nausea,(PUQE) 14 days PUQE scale is divided into three dimensions, namely nausea, vomiting and retching.

Secondary

MeasureTime frame
Mental state score 14 days Self-rating Anxiety Scale (SAS) score;Self-rating Depression Scale (SDS) score,Laboratory tests 14 days human chorionic gonadotropin (HCG);serum levels of vasoactive intestinal peptide (VIP), Motilin (MLT) and Gastrin (GAS)

Countries

China

Contacts

Public ContactChen Yulan

School of Medicine, University of Electronic Science and Technology of China

cyl183984180222022@163.com18780370757

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026